CNX selected for Inflexion’s record $3 billion fund

London-based specialty pharmaceutical company CNX Therapeutics is set to fast-track its European growth strategy after being chosen as one of four portfolio companies for Inflexion’s new Continuation Fund, which closed at £2.3 billion ($3 billion). The fund, the largest of its kind raised in Europe to date, aims to support high-performing businesses with significant growth potential.

The move is expected to give CNX Therapeutics enhanced capacity to pursue acquisitions and in-licensing deals across Europe. The company, which supplies essential medicines to over 50 countries, will leverage Inflexion’s ongoing investment and sector expertise to strengthen its position in the mid-market pharmaceutical sector. 

This latest development follows a period of rapid expansion for CNX, which has quadrupled its revenues since Inflexion first carved it out of Sunovion Pharmaceuticals’ European operations in 2021. Recent years have seen CNX broaden its hospital-injectable and CNS product portfolios through acquisitions from companies including Clinigen, Sanofi, and Eisai.